Table 3.
Case | Clinical diagnosis | Pathologic group | Sex | Age at scan, yrs | Scan to death, yrs | Core clinical features of DLB | DaTQUANT putamen z-score | PiB SUVr | FDG CIS ratio | MRI HP/TIV | Lewy related pathology | AD neuropathological change | Braak NFT staging |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | DLB | LBD | M | 77 | 4 | 3 | −4.39 | 1.31 | 1.06 | 0.452 | Neocortical (diffuse) | Low | III |
2 | DLB | LBD | M | 77 | 4 | 3 | −2.38 | 1.65 | 1.20 | 0.502 | Neocortical (diffuse) | Low | II |
3 | DLB | LBD | M | 75 | 5 | 4 | −3.57 | 1.53 | 1.20 | 0.534 | Neocortical (diffuse) | Low | II |
4 | DLB | LBD | M | 89 | 6 | 4 | −4.03 | 1.34 | 1.12 | 0.341 | Neocortical (diffuse) | Not | II |
5 | DLB | LBD | M | 61 | 6 | 4 | −4.34 | 1.17 | 1.03 | 0.488 | Neocortical (diffuse) | Not | None |
6 | DLB | LBD | M | 71 | 5 | 2 | −4.76 | 1.33 | 1.19 | 0.465 | Neocortical (diffuse) | Low | II |
7 | DLB | LBD | M | 74 | 2 | 3 | −2.39 | 2.22 | 1.06 | 0.459 | Neocortical (diffuse) | Low | III |
8 | DLB | LBD + AD | M | 63 | 6 | 3 | −2.37 | 1.59 | 1.17 | 0.489 | Neocortical (diffuse) | Intermediate | V |
9 | DLB | LBD + AD | M | 74 | 1 | 2 | −3.69 | 2.07 | 1.11 | 0.441 | Neocortical (diffuse) | Intermediate | III |
10 | ADem | LBD + AD | F | 75 | 2 | 0 | −4.52 | 2.42 | 0.99 | 0.380 | Neocortical (diffuse) | High | V |
11 | ADem | LBD + AD | F | 63 | 3 | 0 | 0.78 | 2.63 | 0.90 | 0.487 | Neocortical (diffuse) | High | V |
12 | ADem | AD | M | 59 | 3 | 0 | −0.54 | 2.22 | 0.77 | 0.428 | None | Intermediate | IV |
13 | ADem | AD | M | 74 | 5 | 0 | 0.02 | 1.86 | 1.00 | 0.388 | Amygdala-predominant | High | VI |